Site of metastasis in metastatic clear cell renal cell carcinoma (mccRCC) and outcome of treatment with sunitinib

被引：2
|
作者：
Beuselinck, B.
Rixe, O.
Oudard, S.
Wolter, P.
Ayllon, J.
Elaidi, R.
Schoffski, P.
Scotte, F.
Zucman-Rossi, J.
Medioni, J.
机构：
[1] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[2] Univ Cincinnati, Div Hematol Oncol, Expt Therapeut Program, Cincinnati, OH USA
[3] Catholic Univ Louvain, Leuven Canc Inst, B-3000 Louvain, Belgium
[4] INSERM, Genom Fonct Tumeurs Solides U674, Paris, France
[5] Georges Pompidou European Hosp, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e15065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15065
引用
收藏
页数：1
相关论文
共 50 条
  • [21] 124I-cG250 PET scan for early detection of response to sunitinib in patients (Pts) with metastatic clear cell renal cell carcinoma (MccRCC).
    Larson, Steven M.
    Motzer, Robert John
    Pandit-Taskar, Neeta
    Bartz, Roman
    Feldman, Darren Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [22] Treatment with male sunitinib with clear cell renal cell carcinoma and metabolic syndrome
    Czastkiewicz-Trawinska, Diana
    Kaiser, Andrzej
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : A13 - A14
  • [23] Sunitinib for metastatic renal cell carcinoma
    Mukherji, Deborah
    Larkin, James
    Pickering, Lisa
    FUTURE ONCOLOGY, 2010, 6 (09) : 1377 - 1385
  • [24] Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma
    Keizman, Daniel
    Ish-Shalom, Maya
    Sella, Avishay
    Gottfried, Maya
    Maimon, Natalie
    Peer, Avivit
    Hammers, Hans
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Neiman, Victoria
    Rosenbaum, Eli
    Sarid, David
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael A.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : 420 - 425
  • [25] Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC).
    Guida, Annalisa
    Le Teuff, Gwenael
    Silva, Carolina Alveosta
    Blameble, Emeline Colomba
    Salviat, Flore
    Baciarello, Giulia
    Derosa, Lisa
    Loriot, Yohann
    Fizazi, Karim
    Di Palma, Mario
    Massard, Christophe
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [26] Looking for predictive biomarkers for sunitinib in metastatic renal clear cell carcinoma (mRCC)
    Maroto, P.
    Esteban, E.
    Méndez-Vidal, M. J.
    Fernandez-Parra, E. M.
    Leon, L.
    Perez-Valderrama, B.
    Domenech, M.
    Calderero, V.
    Perez-Gracia, J. L.
    Algaba, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S676 - S676
  • [27] THE EFFECTS OF PAZOPANIB VERSUS SUNITINIB ON RENAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA
    Lee, Eun Jeong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 561 - 561
  • [28] Nomogram for Predicting Resistance to Sunitinib in Patients with Metastatic Clear Cell Renal Carcinoma
    Kammerer-Jacquet, S-F
    Belaud-Rotureau, M-A
    Oger, E.
    Verhoest, G.
    Lespagnol, A.
    Edeline, J.
    Jaillard, S.
    Laguerre, B.
    Vauleon, E.
    Mosser, J.
    Bensalah, K.
    Rioux-Leclercq, N.
    LABORATORY INVESTIGATION, 2014, 94 : 238A - 238A
  • [29] Immune expression profile and sunitinib benefit in metastatic clear cell renal cell carcinoma (ccRCC)
    Reig Torras, O.
    Marin-Aguilera, M.
    Jimenez, N.
    Pare, L.
    Galvan, P.
    Mallofre, C.
    Prat, A.
    Mellado Gonzalez, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib
    Cetin, Bulent
    Gonul, Ipek Isik
    Gumusay, Ozge
    Afsar, Baris
    Bilgetekin, Irem
    Ozet, Ahmet
    Uner, Aytug
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 408 - 413
12345